Clinical trials: COVID-19 Prevention
Covid19, Venous Thromboembolism
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
- Trial name
- MICHELLE (NCT04662684)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- Science Valley Research Institute
SARS-CoV-2
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
- Trial name
- COLSTAT (NCT04472611)
- Testing
- Standard of Care (SOC) and Colchicine+Rosuvastatin
- Where
- 4 sites in United States
- Volunteers
- 250 people
- Sponsor
- Yale University
COVID
A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic
Prophylactic treatment in cancer patients undergoing antineoplastic therapy during the COVID-19 pandemic.
- Trial name
- NCT04369365
- Testing
- Azithromycin 500 milligram (mg) oral Tablet
- Where
- Austria
- Volunteers
- 74 people
- Sponsor
- Prof. Dr. Matthias Preusser
Covid19
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with…
- Trial name
- NCT05016934
- Testing
- A vaccine composed of a recombinant S1 antigen
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital do Coracao
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Sars-CoV-2 Infection
Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection
This is a phase 2b prospective, randomized, single-blind, controlled trial of a single subcutaneous injection of peginterferon lambda-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at…
- Trial name
- PROTECT (NCT04344600)
- Testing
- Peginterferon lambda alfa-1a subcutaneous injection, Saline
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
COVID-19, Corona Virus Infection
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
This a double-blind, randomized, placebo-controlled clinical trial to determine if primary prophylaxis with hydroxychloroquine in healthcare workers reduces symptomatic COVID-19 infection.
- Conditions
- COVID-19, Corona Virus Infection, Wuhan Coronavirus, Prophylaxis
- Trial name
- HCQPreP (NCT04363450)
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Cancer, Covid-19
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
The purpose of this study is to find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.
- Trial name
- COV-IMMUNO (NCT04442048)
- Testing
- IMM-101, Observation
- Where
- 8 sites in Canada
- Volunteers
- 195 people
- Sponsor
- Canadian Cancer Trials Group
COVID-19, SARS-CoV 2
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
This is a prospective, double-blind, randomized, placebo-controlled study in two distinct cohorts to evaluate the efficacy and safety of hydroxychloroquine in the prevention of COVID-19 infection.
- Trial name
- NCT04372017
- Testing
- Hydroxychloroquine, Vitamin D
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sanford Health
Mental Health Wellness 1, COVID
Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19
A pragmatic superiority randomized controlled trial comparing Telepsychoeducation plus personalized videos vs. Telepsychoeducation without personalized videos for the prevention of future emotional distress in professionals and…
- Conditions
- Mental Health Wellness 1, COVID, Emotional Distress, Depressive Symptoms
- Trial name
- NCT04632082
- Testing
- Telepsychoeducation with personalized videos, Telepsychoeducation without personalized videos
- Where
- Brazil
- Volunteers
- 2,200 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Prevention of Infectious Disease Caused by SARS-CoV-2
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA
This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration…
- Trial name
- NCT05135455
- Where
- 6 sites in Japan
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
COVID-19
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19
Protocol bacTRL-Spike-1 will be the first-in-human study of bacTRL-Spike, and the first-in-human use of orally delivered bacTRL.
- Trial name
- NCT04334980
- Testing
- bacTRL-Spike
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Symvivo Corporation
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198102
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Study for Efficacy and Safety Assessment of the Drug RADAMIN®VIRO for COVID-19 Postexposure Prophylaxis
This is Double-Blind, Placebo-Controlled Multicentre Clinical Phase III Study conducted in 10 medical facilities. The objective of the study is to evaluate efficacy and safety of the drug Drug RADAMIN®VIRO, Lyophilisate for…
- Trial name
- NCT05722691
- Testing
- Double-Stranded RNA sodium salt
- Where
- 10 sites in Russia
- Volunteers
- 800 people
- Sponsor
- Promomed, LLC
Covid19, Severe Acute Respiratory Syndrome
Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19
Pilot clinical trial, with a marketed drug -natural component of human plasma-, not approved for this indication, single-center, exploratory, open, randomized, controlled, to study the efficacy and safety of human Antithrombin in…
- Conditions
- Covid19, Severe Acute Respiratory Syndrome, Distress Respiratory Syndrome
- Trial name
- NCT04745442
- Testing
- Antithrombin + best available treatment, Best available treatment
- Where
- Spain
- Volunteers
- 48 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
HIV-1-infection, Hypertension
Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV
Social distancing measures put in place to combat the COVID-19 disease pandemic may increase social isolation and impact cardiovascular disease prevention behaviors among people living with HIV (PLWH).
- Trial name
- AAIM-High (NCT04661813)
- Testing
- EXTRA-CVD Virtual Care
- Where
- 3 sites in United States
- Volunteers
- 81 people
- Sponsor
- Case Western Reserve University
COVID
Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2
Trial design. Randomized, double-blind, placebo-controlled trial in a catchment population of 2,020,860 age-appropriate subjects in the state of Buenos Aires and 235,000 in the city of Buenos Aires. Institutions.
- Trial name
- NCT04479163
- Testing
- Convalescent Plasma
- Where
- 11 sites in Argentina
- Volunteers
- 165 people
- Sponsor
- Fundacion Infant
Cancer, COVID
Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection
Ivermectin plus losartan as prophilaxy to severe events in patients with cancer with recent diagnosis of COVID-19
- Conditions
- Cancer, COVID, Coronavirus Infection
- Trial name
- TITAN (NCT04447235)
- Testing
- Ivermectin, Losartan
- Where
- Brazil
- Volunteers
- 77 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Coronavirus Infections
Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis
We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the…
- Trial name
- NCT04384458
- Testing
- Hydroxychloroquine, Ivermectin
- Where
- Brazil
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Covid19 Prevention
Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19
Randomized, double-blind (blinded for the trial subject and the study physician), placebo controlled, multi-center clinical trial in parallel assignment of efficacy, immunogenicity, and safety of the Gam-COVID-Vac combined vector…
- Trial name
- RESIST (NCT04530396)
- Testing
- Gam-COVID-Vac
- Where
- 23 sites in Russia
- Volunteers
- 33,758 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation